argenx NV ADR (ARGX)vsBio Green Med Solution, Inc. (BGMS)
ARGX
argenx NV ADR
$853.82
-2.15%
HEALTHCARE · Cap: $54.24B
BGMS
Bio Green Med Solution, Inc.
$0.89
-2.51%
HEALTHCARE · Cap: $4.94M
Smart Verdict
WallStSmart Research — data-driven comparison
argenx NV ADR generates 348455% more annual revenue ($5.32B vs $1.52M). ARGX leads profitability with a 32.3% profit margin vs -204.2%. BGMS trades at a lower P/E of 0.2x. ARGX earns a higher WallStSmart Score of 73/100 (B).
ARGX
Strong Buy73
out of 100
Grade: B
BGMS
Hold45
out of 100
Grade: D
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+65.6%
Fair Value
$2427.69
Current Price
$853.82
$1573.87 discount
Intrinsic value data unavailable for BGMS.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Every $100 of equity generates 31 in profit
Keeps 32 of every $100 in revenue as profit
Strong operational efficiency at 32.0%
Revenue surging 59.3% year-over-year
Earnings expanding 95.2% YoY
Conservative balance sheet, low leverage
Attractively priced relative to earnings
Reasonable price relative to book value
Revenue surging 710.0% year-over-year
Areas to Watch
Premium valuation, high expectations priced in
Weak financial health signals
Trading at 180.5x book value
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -46.1% — below average capital efficiency
Negative free cash flow — burning cash
Comparative Analysis Report
WallStSmart ResearchBull Case : ARGX
The strongest argument for ARGX centers on Return on Equity, Profit Margin, Operating Margin. Profitability is solid with margins at 32.3% and operating margin at 32.0%. Revenue growth of 59.3% demonstrates continued momentum.
Bull Case : BGMS
The strongest argument for BGMS centers on P/E Ratio, Price/Book, Revenue Growth. Revenue growth of 710.0% demonstrates continued momentum.
Bear Case : ARGX
The primary concerns for ARGX are P/E Ratio, Piotroski F-Score, Price/Book.
Bear Case : BGMS
The primary concerns for BGMS are EPS Growth, Market Cap, Return on Equity.
Key Dynamics to Monitor
ARGX profiles as a growth stock while BGMS is a hypergrowth play — different risk/reward profiles.
ARGX carries more volatility with a beta of -0.02 — expect wider price swings.
BGMS is growing revenue faster at 710.0% — sustainability is the question.
Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.
Bottom Line
ARGX scores higher overall (73/100 vs 45/100), backed by strong 32.3% margins and 59.3% revenue growth. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
argenx NV ADR
HEALTHCARE · BIOTECHNOLOGY · USA
argenx SE, a clinical-phase biotechnology company, focuses on the development of antibody-based therapies for the treatment of autoimmune diseases, hematology and cancer. The company is headquartered in Breda, the Netherlands.
Bio Green Med Solution, Inc.
HEALTHCARE · BIOTECHNOLOGY · USA
Bio Green Med Solution, Inc. engages in the distributing, trading, and installation of protective and fire safety materials and equipment, and fire protection and prevention systems. The company is headquartered in Kuala Lumpur, Malaysia.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?